Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab versus optimized medical therapy for stricturing Crohn's disease
ACTRN12626001144303Phase 4Not yet recruiting
- Sponsor
- Sydney Local Health District
- Start
- Jan 2027
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 4, randomised, open-label trial of guselkumab in Crohn's disease (2 arms), sponsored by Sydney Local Health District. Primary endpoint: Complete endoscopic resolution of all strictures. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
guselkumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on ACTRN12626001144303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626001144303.